Healthcare provider profile · identity verified

Rodney Lewis Smith, MD

Allopathic & Osteopathic Physicians|General Practice · GAINESVILLE, GA · NPI 1144290917

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Rodney Lewis Smith, MD received $117.06 in general payments during 2025 across 5 reported records.

Inspire Medical Systems, Inc. accounted for 54.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$117.06

5 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Inspire Medical Systems, Inc.	Unresolved — no canonical attribution shown	$63.97	54.6%	1	2025
PFIZER INC.	Unresolved — no canonical attribution shown	$29.42	25.1%	2	2025
Boston Scientific Corporation	Unresolved — no canonical attribution shown	$16.94	14.5%	1	2025
Phathom Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$6.73	5.8%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$117.06	5

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
INSPIRE Normalized: inspire	Device	Inspire Medical Systems, Inc.	$63.97	1	2025
Source payment records 2025-01-28 · Inspire Medical Systems, Inc. · $63.97 · Open Payments source
PREVNAR 20 Normalized: prevnar 20	Biological	PFIZER INC.	$29.42	2	2025
Source payment records 2025-03-03 · PFIZER INC. · $14.44 · Open Payments source 2025-06-11 · PFIZER INC. · $14.98 · Open Payments source
General - Pain Management Normalized: general pain management	Device	Boston Scientific Corporation	$16.94	1	2025
Source payment records 2025-07-15 · Boston Scientific Corporation · $16.94 · Open Payments source
VOQUEZNA Normalized: voquezna	Drug	Phathom Pharmaceuticals, Inc.	$6.73	1	2025
Source payment records 2025-03-18 · Phathom Pharmaceuticals, Inc. · $6.73 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	106	20

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Propranolol Hcl	Propranolol Hcl	1042	263
Atorvastatin Calcium	Atorvastatin Calcium	1024	265
Montelukast Sodium	Montelukast Sodium	817	210
Amlodipine Besylate	Amlodipine Besylate	624	181
Lisinopril	Lisinopril	592	152
Omeprazole	Omeprazole	527	135
Metformin Hcl	Metformin Hcl	515	131
Gabapentin	Gabapentin	474	126
Diclofenac Sodium	Diclofenac Sodium	455	109
Levothyroxine Sodium	Levothyroxine Sodium	428	102
Escitalopram Oxalate	Escitalopram Oxalate	372	86
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	324	51
Allopurinol	Allopurinol	321	84
Pantoprazole Sodium	Pantoprazole Sodium	280	71
Hydrochlorothiazide	Hydrochlorothiazide	277	85
Albuterol Sulfate Hfa	Albuterol Sulfate	263	70
Tamsulosin Hcl	Tamsulosin Hcl	246	63
Glimepiride	Glimepiride	231	52
Losartan Potassium	Losartan Potassium	231	73
Rosuvastatin Calcium	Rosuvastatin Calcium	197	56
Azelastine Hcl	Azelastine Hcl	195	84
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	193	74
Potassium Chloride	Potassium Chloride	191	45
Alendronate Sodium	Alendronate Sodium	188	39
Fluoxetine Hcl	Fluoxetine Hcl	187	41
Furosemide	Furosemide	180	50
Simvastatin	Simvastatin	176	42
Trazodone Hcl	Trazodone Hcl	161	47
Tramadol Hcl	Tramadol Hcl	160	68
Vascepa	Icosapent Ethyl	147	31
Buspirone Hcl	Buspirone Hcl	144	33
Dutasteride	Dutasteride	143	33
Vraylar	Cariprazine Hcl	142	28
Farxiga	Dapagliflozin Propanediol	141	25
Fluticasone Propionate	Fluticasone Propionate	138	36
Clonazepam	Clonazepam	136	56
Metoprolol Tartrate	Metoprolol Tartrate	133	40
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	115	22
Metoprolol Succinate	Metoprolol Succinate	115	35
Ropinirole Hcl	Ropinirole Hcl	115	27
Ezetimibe	Ezetimibe	107	30
Myrbetriq	Mirabegron	107	26
Eliquis	Apixaban	106	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	106	26
Fenofibrate	Fenofibrate,micronized	105	17
Amitriptyline Hcl	Amitriptyline Hcl	104	30
Clonidine Hcl	Clonidine Hcl	104	29
Meclizine Hcl	Meclizine Hcl	101	35
Famotidine	Famotidine	98	34
Synthroid	Levothyroxine Sodium	98	26
Aripiprazole	Aripiprazole	93	14
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	92	34
Carvedilol	Carvedilol	91	28
Clopidogrel	Clopidogrel Bisulfate	91	32
Meloxicam	Meloxicam	81	19
Januvia	Sitagliptin Phosphate	79	15
Trulicity	Dulaglutide	79	17
Sertraline Hcl	Sertraline Hcl	77	21
Venlafaxine Hcl Er	Venlafaxine Hcl	77	20
Duloxetine Hcl	Duloxetine Hcl	69	17
Bupropion Hcl Sr	Bupropion Hcl	68	15
Ibuprofen	Ibuprofen	67	17
Pravastatin Sodium	Pravastatin Sodium	65	19
Dicyclomine Hcl	Dicyclomine Hcl	64	19
Lactulose	Lactulose	64	27
Divalproex Sodium Er	Divalproex Sodium	62	20
Lovastatin	Lovastatin	61	12
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	58	suppressed
Metformin Hcl Er	Metformin Hcl	57	18
Ketoconazole	Ketoconazole	56	14
Quetiapine Fumarate	Quetiapine Fumarate	55	14
Topiramate	Topiramate	54	13
Celecoxib	Celecoxib	53	13
Ondansetron Hcl	Ondansetron Hcl	53	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	52	14
Warfarin Sodium	Warfarin Sodium	52	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	51	16
Fenofibrate	Fenofibrate	50	15
Atenolol	Atenolol	49	12
Colchicine	Colchicine	49	13
Estradiol	Estradiol	49	12
Lamotrigine	Lamotrigine	48	11
Ozempic	Semaglutide	47	11
Ventolin Hfa	Albuterol Sulfate	47	14
Pioglitazone Hcl	Pioglitazone Hcl	46	12
Baclofen	Baclofen	45	suppressed
Citalopram Hbr	Citalopram Hydrobromide	44	14
Finasteride	Finasteride	43	11
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	42	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	40	suppressed
Temazepam	Temazepam	40	14
Tresiba Flextouch U-100	Insulin Degludec	40	suppressed
Jardiance	Empagliflozin	38	suppressed
Ondansetron Odt	Ondansetron	37	14
Tresiba Flextouch U-200	Insulin Degludec	37	suppressed
Donepezil Hcl	Donepezil Hcl	36	suppressed
Novolog Flexpen	Insulin Aspart	35	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	34	suppressed
Bupropion Xl	Bupropion Hcl	33	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	33	suppressed
Valacyclovir	Valacyclovir Hcl	33	12
Breo Ellipta	Fluticasone/Vilanterol	32	suppressed
Promethazine Hcl	Promethazine Hcl	31	suppressed
Spironolactone	Spironolactone	31	11
Cholestyramine	Cholestyramine (With Sugar)	30	suppressed
Tizanidine Hcl	Tizanidine Hcl	30	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	27	suppressed
Gemfibrozil	Gemfibrozil	27	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	26	suppressed
Humalog Kwikpen U-100	Insulin Lispro	25	suppressed
Mometasone Furoate	Mometasone Furoate	25	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	suppressed
Constulose	Lactulose	24	suppressed
Klor-Con M20	Potassium Chloride	24	suppressed
Levetiracetam	Levetiracetam	24	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	24	suppressed
Acyclovir	Acyclovir	23	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Glipizide	Glipizide	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Raloxifene Hcl	Raloxifene Hcl	20	suppressed
Diazepam	Diazepam	19	suppressed
Kerendia	Finerenone	19	suppressed
Linzess	Linaclotide	19	suppressed
Lorazepam	Lorazepam	19	suppressed
Mupirocin	Mupirocin	19	15
Rizatriptan	Rizatriptan Benzoate	19	suppressed
Fluconazole	Fluconazole	18	17
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	13
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Ranolazine Er	Ranolazine	17	suppressed
Cephalexin	Cephalexin	16	14
Chlorthalidone	Chlorthalidone	16	suppressed
Dexlansoprazole Dr	Dexlansoprazole	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Primidone	Primidone	16	suppressed
Tradjenta	Linagliptin	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	15	suppressed
Icosapent Ethyl	Icosapent Ethyl	15	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	15	suppressed
Nebivolol Hcl	Nebivolol Hcl	15	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Terconazole	Terconazole	15	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	14	suppressed
Doxepin Hcl	Doxepin Hcl	14	suppressed
Gemtesa	Vibegron	14	suppressed
Premarin	Estrogens, Conjugated	14	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	13	suppressed
Metformin Er Gastric	Metformin Hcl	13	suppressed
Metronidazole	Metronidazole	13	12
Mirtazapine	Mirtazapine	13	suppressed
Unifine Pentips	Pen Needle, Diabetic	13	suppressed
Calcitriol	Calcitriol	12	suppressed
Cilostazol	Cilostazol	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Niacin Er	Niacin	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Prempro	Estrogen,con/M-Progest Acet	12	suppressed
Trintellix	Vortioxetine Hydrobromide	12	suppressed
Unifine Pentips Plus	Pen Needle, Diabetic	12	suppressed
Zonisamide	Zonisamide	12	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	11	suppressed
Fesoterodine Fumarate Er	Fesoterodine Fumarate	11	suppressed
Lidocaine-Prilocaine	Lidocaine/Prilocaine	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Olanzapine	Olanzapine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$117.06 · 5 records	Inspire Medical Systems, Inc.	General - Pain Management, INSPIRE, PREVNAR 20, VOQUEZNA	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error